The content is available as a PDF (419.7 KB).
Electronic Supplementary Material
40699_2022_4190_MOESM1_ESM.pdf (581.2KB, pdf)
Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients
Acknowledgments and disclosures
Acknowledgment: The patients in this manuscript gave written informed consent to publication of their case details. Conflict of interest: none.
Footnotes
These authors contributed equally
References
- 1.Culton DA, Diaz LA. Treatment of subepidermal immunobullous diseases. Clin Dermatol. 2012;30:95–102. doi: 10.1016/j.clindermatol.2011.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Brit J Dermatol. 2015;172:867–77. doi: 10.1111/bjd.13717. [DOI] [PubMed] [Google Scholar]
- 3.Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83:46–52. doi: 10.1016/j.jaad.2020.01.089. [DOI] [PubMed] [Google Scholar]
- 4.Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154:1225–6. doi: 10.1001/jamadermatol.2018.2526. [DOI] [PubMed] [Google Scholar]
- 5.Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol. 2020;11:611549. doi: 10.3389/fimmu.2020.611549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Seidman JSE, Dawn ZO, Charisse M. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol Online J 2019; 25: 13030/qt25q9w6r9. [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
40699_2022_4190_MOESM1_ESM.pdf (581.2KB, pdf)
Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients